Healthcare
Upcoming Earnings
Medical

Novartis

$94.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$4.03 (4.47%) Today
-$0.26 (-0.28%) As of 6:07 PM EDT after-hours

Why Robinhood?

You can buy or sell Novartis and other stocks, options, ETFs, and crypto commission-free!

About NVS

Novartis AG, also called Novartis, is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. Read More The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Employees
125,161
Headquarters
Basel, Basel-Stadt (Basle Town)
Founded
1996
Market Cap
209.59B
Price-Earnings Ratio
16.98
Dividend Yield
2.15
Average Volume
2.25M
High Today
$95.00
Low Today
$93.35
Open Price
$94.82
Volume
5.45M
52 Week High
$96.31
52 Week Low
$74.97

Collections

Healthcare
Upcoming Earnings
Medical
Pharmaceutical
Manufacturing
Health
Technology

NVS News

Reuters11h

BRIEF-Novartis CEO Says U.S. Gov't Policy Environment Very Fluid

31
Benzinga12h

Novartis Trades Higher On Q2 Earnings, Guidance Raise

48
Bloomberg15h

Novartis’s Brightened Outlook Pushes Shares to All-Time High

7

NVS Earnings

$1.20
$1.25
$1.29
$1.34
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
$1.22 per share
Actual
$1.34 per share

More NVS News

MarketWatch16h

Novartis hikes sales, operating income forecast

52
BenzingaJul 16

FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab

68
ReutersJul 11

BRIEF-Novartis, Amgen And Banner Alzheimer's Institute Discontinue Clinical Program With Bace Inhibitor CNP520

125
ReutersJul 9

Novartis to sell epinephrine shot in U.S. pharmacies amid EpiPen shortage

351
ReutersJul 9

Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage

143
ReutersJul 2

BRIEF-Novartis to launch generic Iressa when patent expires in Europe

102
BenzingaJul 1

Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio

124
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.